PD-1 x IL-2 antibody fusions: The next Keytruda competitors?

With a series of positive ASCO readouts, Innovent believes it may have found the next immunotherapy to rival Keytruda — and one that could treat cold tumors PD-1 blockers have failed to address.

The company’s PD-1 x IL-2 antibody fusion has shown efficacy signals in three settings where PD-1 blockade has limited efficacy. The question now is whether those results will hold up in registrational studies, and whether immunocytokines could be the modality that finally unlocks IL-2’s long-promised potential...